Testing empagliflozin and diet advice for kidney stone prevention
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if a medication called empagliflozin, combined with personalized diet advice, can help prevent kidney stones from coming back. It may be an option if you've had two or more kidney stone events in the last 10 years and your stones were mostly calcium-based.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had at least 2 kidney stones in the last 10 years
- Your last stone was made mostly of calcium oxalate, calcium phosphate, or a mix of both
- You are 18 years or older
- If you take medications for stone prevention, you have been on the same dose for at least 60 days and can stay on it during the study
- You do not have type 1 diabetes, severe kidney disease, heart failure, or a history of ketoacidosis
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for better ways to predict when kidney stones may come back and what complications might happen. It may help doctors personalize follow-up and prevention plans based on information collected from you.
This trial tests if a diabetes medication (SGLT2i) can help prevent calcium kidney stones. Researchers want to see if it changes the way your urine absorbs and processes minerals.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Hear when a new Kidney Stone trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.